TY - JOUR
T1 - Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes
T2 - Consensus statements and report from a working conference
AU - Valent, Peter
AU - Horny, Hans Peter
AU - Bennett, John M.
AU - Fonatsch, Christa
AU - Germing, Ulrich
AU - Greenberg, Peter
AU - Haferlach, Torsten
AU - Haase, Detlef
AU - Kolb, Hans Jochen
AU - Krieger, Otto
AU - Loken, Michael
AU - van de Loosdrecht, Arjan
AU - Ogata, Kiyoyuki
AU - Orfao, Alberto
AU - Pfeilstöcker, Michael
AU - Rüter, Björn
AU - Sperr, Wolfgang R.
AU - Stauder, Reinhard
AU - Wells, Denise A.
PY - 2007/6
Y1 - 2007/6
N2 - The classification, scoring systems, and response criteria for myelodysplastic syndromes (MDS) have recently been updated and have become widely accepted. In addition, several new effective targeted drugs for patients with MDS have been developed. The current article provides a summary of updated and newly proposed markers, criteria, and standards in MDS, with special reference to the diagnostic interface and refinements in evaluations and scoring. Concerning the diagnostic interface, minimal diagnostic criteria for MDS are proposed, and for patients with unexplained cytopenia who do not fulfill these criteria, the term 'idiopathic cytopenia of uncertain significance' (ICUS) is suggested. In addition, new diagnostic and prognostic parameters, histopathologic and immunologic determinants, proposed refinements in scoring systems, and new therapeutic approaches are discussed. Respective algorithms and recommendations should facilitate diagnostic and prognostic evaluations in MDS, selection of patients for therapies, and the conduct of clinical trials.
AB - The classification, scoring systems, and response criteria for myelodysplastic syndromes (MDS) have recently been updated and have become widely accepted. In addition, several new effective targeted drugs for patients with MDS have been developed. The current article provides a summary of updated and newly proposed markers, criteria, and standards in MDS, with special reference to the diagnostic interface and refinements in evaluations and scoring. Concerning the diagnostic interface, minimal diagnostic criteria for MDS are proposed, and for patients with unexplained cytopenia who do not fulfill these criteria, the term 'idiopathic cytopenia of uncertain significance' (ICUS) is suggested. In addition, new diagnostic and prognostic parameters, histopathologic and immunologic determinants, proposed refinements in scoring systems, and new therapeutic approaches are discussed. Respective algorithms and recommendations should facilitate diagnostic and prognostic evaluations in MDS, selection of patients for therapies, and the conduct of clinical trials.
KW - Criteria
KW - ICUS
KW - Minimal diagnostic criteria
KW - Myelodysplastic syndromes
KW - Patient selection
KW - Standardization
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=34249786233&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2006.11.009
DO - 10.1016/j.leukres.2006.11.009
M3 - Comment/debate
C2 - 17257673
AN - SCOPUS:34249786233
SN - 0145-2126
VL - 31
SP - 727
EP - 736
JO - Leukemia Research
JF - Leukemia Research
IS - 6
ER -
